Venture capitalists are still spending big on biotech companies, even four months after the coronavirus pandemic cratered global markets.
Venture capitalists have already signed 240 biotech deals this year, collectively worth more than $10 billion, according to a recent SVB analysis. The average valuation for those companies has also increased since January, despite concerns about the potential impact of clinical trial delays.
About the Author Reprints
